Fatal Thrombocytopaenia Temporally Related to the Administration of Alemtuzumab (MabCampath) for Refractory CLL Despite Early Discontinuation of Therapy

Hematology - United Kingdom
doi 10.1080/10245330400001942
Full Text
Abstract

Available in full text

Categories
Hematology
Date
Authors
Publisher

Informa UK Limited

Related search

Low-Dose Subcutaneous Alemtuzumab in Refractory Chronic Lymphocytic Leukaemia (CLL): Results of a Prospective, Single-Arm Multicentre Study

Leukemia
Cancer ResearchOncologyAnesthesiologyPain MedicineHematology
2009English

The First Case of Biological Therapy Discontinuation After a Complete Remission Induced by Maintenance Therapy With Adalimumab for Refractory Ulcerative Colitis

Journal of Clinical Medicine Research
2015English

Filgrastim and Alemtuzumab (Campath-1h) for Refractory Chronic Lymphocytic Leukemia

Leukemia
Cancer ResearchOncologyAnesthesiologyPain MedicineHematology
2005English

Infusion Reactions Related to Infliximab Therapy Are Not Usually Associated With Drug Discontinuation

Journal of Rheumatology
RheumatologyAllergyImmunology
2012English

Analysis of Treatment Options for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2014English

Rescue Therapy for Refractory ARDS Should Be Offered Early: No

Intensive Care Medicine
Critical CareIntensive Care Medicine
2015English

Fatal Pseudomembranous Colitis Despite Eradication of Clostridium Difficile.

BMJ
1981English

Rescue Therapy for Refractory ARDS Should Be Offered Early: Yes

Intensive Care Medicine
Critical CareIntensive Care Medicine
2015English

Hormone Therapy Discontinuation

Menopause
GynecologyObstetrics
2010English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy